5月20日，60位投资者走进北交所。北交所工作人员带领投资者参观了仪式大厅、模拟体验了上市敲钟 仪式，并向投资者讲解了北交所的设立背景和市场发展现状。通过参观和学习，投资者进一步了解北交 所的发展历程。 5月21日，北交所投教基地联合中信建投证券投教基地面向中国人民大学经济学院师生进行授课，为在 校学生介绍多层次资本市场概况及新三板、北交所设立背景、市场定位及特色制度。同时，普及防范非 法证券活动知识，提升在校学生风险识别防范意识。 5月21日，北交所投教基地联合中信建投证券投教基地开展"投资者零距离"——走进广厦环能活动。20 余名投资者通过实地调研参观，了解公司发展情况，并与公司高管开展面对面的问答交流。通过本次活 动，投资者更加了解上市公司，也搭建了投资者与上市公司的良好沟通平台。 编辑 陈莉 校对 穆祥桐 新京报贝壳财经讯(记者张晓翀)5月29日，记者从北京证券交易所（简称"北交所")获悉，近日北交所举 办投资者服务北京站活动。 5月16日，北交所举办"讲述我与北交所的投资故事"——老股民座谈会，邀请8位资深投资者代表分享故 事，倡导理性投资理念，同时就加强投资者权益保护、促进北交所市场高质量发展方面 ...

Core Viewpoint - A class action lawsuit has been filed against Viatris Inc. for allegedly misleading investors regarding the company's revenue and growth challenges, particularly related to a failed FDA inspection at its Indore facility [3][4]. Group 1: Class Action Details - The class action represents investors who purchased Viatris securities between August 8, 2024, and February 26, 2025, with a deadline of June 3, 2025, to file a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and complimentary case evaluations [2]. Group 2: Allegations Against Viatris - The lawsuit claims that Viatris downplayed the seriousness of the failed FDA inspection and its consequences, leading to a false impression of the company's stability [3]. - It is alleged that Viatris underestimated the impact of the FDA inspection failure, which resulted in significant setbacks, including ongoing remediation efforts and disruptions in manufacturing and shipping key products like Lenalidomide [4]. Group 3: Financial Impact - On February 27, 2025, Viatris reported disappointing fourth-quarter and full-year 2024 financial results, along with guidance for fiscal year 2025 that reflected the expected financial effects of the FDA warning letter [5]. - Following this announcement, Viatris' stock price experienced a decline of over 15% [5].

Group 1 - Nvidia is scheduled to provide an investor update that will have implications for shareholders [1]

Welcome to another installment of our BDC Market Weekly Review, where we discuss market activity in the Business Development Company [BDC] sector from both the bottom-up–highlighting individual news and events – as well as the top-down – providing an overview of the broader market.Check out Systematic Income and explore our Income Portfolios, engineered with both yield and risk management considerations. Use our powerful Interactive Investor Tools to navigate the BDC, CEF, OEF, preferred and baby bond mark ...

SAN FRANCISCO, May 22, 2025 (GLOBE NEWSWIRE) -- Biotechnology firm Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is facing a securities class action lawsuit in the Northern District of California, alleging that the company misled investors about its growth potential and ability to capitalize on demand for its cancer treatments. The case, Farberov v. Iovance Biotherapeutics, Inc., et al., centers on statements made between May 9, 2024, and May 8, 2025, a period that includes an expansion from the initial Augu ...

Leadership Changes - Tinder's CEO Faye Iosotaluno is stepping down in July after less than two years in the role, amid challenges in user growth and pressure from activist investors [1][4] - Match Group's CEO Spencer Rascoff will temporarily lead Tinder and has not named a replacement for Iosotaluno [4][5] Activist Investor Influence - Activist investors, including Elliott Management, Starboard Value, and Anson Funds, have acquired significant stakes in Match Group, prompting calls for cost-cutting and margin improvements [6][8] - Match Group signed an agreement with Elliott Management after the activist firm reportedly purchased a $1 billion stake in the company [6] Company Strategy and Performance - Rascoff has initiated a turnaround strategy, including a 13% workforce reduction, primarily affecting Tinder [7] - Iosotaluno previously indicated that Tinder would not return to revenue growth until 2027, while Rascoff expressed optimism about recent product momentum [11] - Tinder is testing new features, such as double-dating options and an AI "wingman" prototype to enhance user engagement [11][12]

Core Insights - Tevogen Bio Holdings Inc. is preparing to provide updates to stockholders ahead of its Annual Meeting scheduled for June 23, 2025, focusing on its innovative business model and strategic growth initiatives [1] Group 1: Portfolio Assets - The company will update investors on its portfolio assets, which include Tevogen Bio Oncology, Tevogen Bio Specialty Care, and Tevogen.AI, valued at over $10 billion as of October 2024 [2] Group 2: Corporate Highlights - Tevogen will detail two strategic initiatives: Tevogen.AI and Tevogen Generics & Biosimilars, alongside plans to expand its operational footprint with an upgraded headquarters [3] Group 3: Financial Market Dynamics - Management is monitoring stock dynamics, noting the impact of a limited tradable float and the growing institutional ownership, which reflects strong investor confidence and long-term holding patterns [4]

华西证券（002926）投教基地则在线上与专家教授面对面，助力社会公众提升金融素养；线下联合华西 科创金融投教基地走进社区、影院等开展普法、防非宣传。 宏信证券红庙子街投教基地及华泰证券四川分公司投教基地分别走进社区、高校及企业，有效宣传非法 荐股风险和理性投资依法维权知识，引导公众正确认识金融风险、防范非法证券期货基金活动。 证券时报.e公司记者从四川证监局了解到，近期，该局围绕"心系投资者携手共行动"，结合投资者保护 相关典型案例、政策法规等，同步开展线上线下（300959）投资者教育系列活动，倡导理性投资和依法 维权，营造全市场保护投资者合法权益的浓厚氛围。 其中，由四川证监局主办的投教集市活动于5月15日在成都市青羊区宽窄巷子举行。该活动结合四川辖 区特色，将川剧、盖碗茶、蜀绣等川蜀文化元素与投教内容相融合，吸引近2万余名市民及游客参加。 华西期货投教基地组织辖区银行、保险、证券期货经营机构、行业自律协会及多所高校负责人，召开主 题座谈会，深入探讨强化投资者教育成果转化、推进投教纳入国民教育工作的创新路径。 首创证券（601136）四川分公司投教基地携手社区持续推出相关投资者教育系列沙龙，通过"知识串 ...

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a securities class action lawsuit for allegedly misleading investors about its growth potential and ability to meet market demand for its cancer treatments [1][2]. Company Overview - Iovance Biotherapeutics is a biotechnology firm that specializes in cancer treatments [1]. - The lawsuit claims that the company and its executives made overly positive statements while concealing material adverse facts about its operational readiness [2][5]. Legal Proceedings - The class action lawsuit is titled Farberov v. Iovance Biotherapeutics, Inc., et al., and covers the period from May 9, 2024, to May 8, 2025 [1][2]. - The lead plaintiff deadline for the lawsuit is set for July 14, 2025 [2]. Financial Impact - On May 9, 2025, Iovance's stock price dropped approximately 44.8%, from $3.17 to $1.75, following the announcement of disappointing financial results and a downward revision of revenue guidance [3]. - The company attributed its lower revenue guidance to a significant reduction in manufacturing capacity and lower-than-expected sales of its existing therapy, Proleukin [4]. Allegations of Misleading Information - The lawsuit argues that the disclosures made by Iovance revealed previously concealed issues that negatively impacted the company's growth prospects [5]. - Investors contend that earlier positive statements misrepresented Iovance's operational readiness and commercialization efforts [5].

案例：不法分子常常编造"天上掉馅饼"的谎言，利用最新高科技理念虚假包装成投资项目，承诺保本且 有高收益，诱导投资者参与。在投资初期，他们信守承诺，按时足额兑付本息，可一旦资金积累到一定 程度，便会卷款潜逃，让投资者血本无归。 防范要点：在投资理财时，投资者应谨记"天上不会掉馅饼，高息保本是陷阱"，高收益往往伴随着高风 险。遇到宣传各种夸张的、具有诱惑性收益的投资产品，投资者应保持冷静理性，警惕"非法集资"的金 融诈骗陷阱，莫被高额回报冲昏头脑。正规的投资理财产品均会充分提示风险，充分披露产品的风险评 级、费用、投资范围、发行托管机构等信息，并要求匹配投资者的风险承受能力，不会承诺保证本金、 保证收益。 "专家内幕"赚大钱？小心投资杀猪盘！ 风险提示：理财非存款，产品有风险，投资须谨慎。 案例：一些不法分子伪装成投资专家，以"内幕消息""经验丰富""AI投资""专家荐股"等为噱头设立钓鱼 群，诱导投资者入群。群内"高手"热聊，展示历史投资高收益，宣传过往精准买卖点，在骗取投资者信 任后，诱骗投资者购买特定投资产品。随着受害者逐步放下戒备不断增加投资后，不法分子便会卷款消 失。 今年5月15日是第七个"全国投资者 ...